Critical Outcome Technologies and Delmar Chemicals Sign Collaboration Agreement
News Sep 12, 2012
Critical Outcome Technologies Inc. and Delmar Chemicals Inc., a Canadian company owned by Holding F.I.S S.p.A announced that they have entered into a research and development collaboration agreement to advance selected small molecules. COTI and Delmar will work together to discover, select, screen and synthesize compounds for targets that have been identified as being of specific interest to major pharmaceutical companies.
Under the agreement, COTI will utilize its proprietary Artificial Intelligence drug discovery platform, CHEMSAS®, to discover and optimize novel drug candidates designed to effectively address a number of highly desirable commercial and therapeutic opportunities. Delmar will take on the medicinal chemistry analysis of the chemical structures as well as the synthesis of the most promising candidates. Strategically, the collaboration leverages the unique technical capabilities and financial resources of both COTI and Delmar in developing patentable preclinical assets for outlicensing.
"We are excited to work with Delmar, a recognized industry leader in medicinal chemistry, to generate additional patentable products for our mutual benefit," said Dr. Wayne Danter, President and Chief Executive Officer of COTI. "This collaboration represents an opportunity to extend the intellectual property in COTI's growing portfolio and assists in positioning CHEMSAS®' as a potential drug discovery engine of choice in the biopharmaceutical and research community."
According to Pierre Plante, President & CEO of Delmar, "We have great confidence in CHEMSAS® and are pleased to be collaborating with COTI on this project. Synthesizing the molecules identified by COTI provides us with a unique opportunity to demonstrate our expertise in medicinal chemistry."
Researchers Develop New Method to Generate Human AntibodiesNews
Researchers hope their approach will help researchers rapidly generate therapeutic antibodies for the treatment of infectious diseases and other conditions such as cancer.READ MORE
U.S. Study of Dapivirine Ring in Lactating Women Finds Little Drug Gets Into Breast MilkNews
The antiretroviral drug dapivirine that is released from an experimental vaginal ring to protect against HIV is absorbed in very low concentrations into breastmilk.READ MORE
Cow Antibodies Yield Important Clues For Developing A Broadly Effective AIDS VaccineNews
The unexpected animal model is providing clues for important questions at a moment when new energy has infused HIV vaccine research.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018